Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 3/20 | 0.35 |
| ▸ | OAT | P04181 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15362631 | 0.88 | GABRR1 (0.39) | SLC1A2SLC1A1GABRR1SLC6A4 | |
| SCHEMBL2178920 | 0.88 | GABRR1 (0.39) | SLC1A2SLC1A1GABRR1SLC6A4 | |
| Hydrochloric Acid SCHEMBL16669413 | 0.86 | SLC1A2 (0.37) | SLC1A2SLC1A1GABRR1SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL1006153 | 0.74 | HSD11B1 (0.40) | — | |
| SCHEMBL965198 | 0.74 | — | — | |
| SCHEMBL16822029 | 0.71 | GAA (0.31) | — | |
| SCHEMBL12914984 | 0.71 | CD81 (0.32) | — | |
| SCHEMBL12914987 | 0.71 | CD81 (0.32) | — | |
| SCHEMBL6121809 | 0.70 | APLNR (0.42) | SLC1A2SLC1A1GABRR1SLC6A4 | |
| SCHEMBL15352277 | 0.70 | APLNR (0.42) | SLC1A2SLC1A1GABRR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067966-B2 | Lupeol-type triterpene derivatives as antivirals | HETERO RESEARCH FOUNDATION, HETERO DRUGS LTD. (IN) | 2015-06-30 | — | — | US | disclosed |
| EP-2454270-B1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2015-02-11 | — | — | EP | disclosed |
| EP-2454270-A2 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | Hetero Research Foundation (IN) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011007230-A2 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | SLC1A2 4703/4885OAT 739/4885SLC1A1 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.